Antioxidant herb purslane flunks its own antioxidant test

Purslane, the leafy plant Portulaca oleracea, has built a reputation in laboratory studies as an antioxidant and anti-inflammatory food. Supplement interest has followed, particularly around metabolic syndrome and its related complications, where low-grade inflammation and oxidative stress are thought to play a role. What has been missing is a clear answer on whether purslane actually shifts these markers in people rather than in cells or animals. This analysis pooled the randomised trial evidence to test whether the preclinical promise survives contact with human blood tests.

The authors systematically searched PubMed/MEDLINE, Web of Science, SCOPUS and Embase for randomised controlled trials of purslane supplementation. They focused on C-reactive protein, a blood marker of inflammation, alongside three markers of oxidative stress: malondialdehyde, total antioxidant capacity and superoxide dismutase. Trials covered metabolic syndrome, its related complications and other diseases. After screening, 10 studies met the eligibility criteria and were pooled, with statistical checks on how much the individual trials disagreed with one another.

Purslane supplementation was linked to a statistically significant fall in C-reactive protein, averaging 0.33 mg/dl, though the result only just crossed the significance threshold and the trials disagreed with each other substantially. The oxidative stress story was flatter: malondialdehyde did not change significantly, nor did total antioxidant capacity, nor superoxide dismutase. In other words, the single inflammation marker moved while all three markers tied to purslane's antioxidant reputation stayed put. The authors conclude that purslane may help decrease CRP but showed no effect on the oxidative stress markers.

This is a familiar pattern in supplement research: strong preclinical antioxidant findings that do not translate cleanly into human trial outcomes. The CRP result keeps purslane interesting as a possible anti-inflammatory food, but the heavy disagreement between trials means the size and reliability of that effect are uncertain. The null findings on the three antioxidant markers complicate the framing that drives most purslane marketing. Open questions include which doses and populations, if any, benefit, and whether a CRP change of this size translates into anything meaningful for health.

If purslane appears in a supplement you take, the fair summary is that pooled human trials show a small drop in one inflammation marker and no change in three antioxidant markers. That is thinner support than the plant's laboratory reputation suggests. A lower CRP reading is a marker, not a health outcome, and the trials behind the pooled figure varied enough that the true effect could be smaller. This is a reason to hold the antioxidant claims loosely rather than a reason to add or drop anything from your routine.